ID   DHI2_HUMAN              Reviewed;         405 AA.
AC   P80365; A7LB28; C5HTY7; Q13194; Q6P2G9; Q8N439; Q96QN8; Q9UC50; Q9UC51;
AC   Q9UCW5; Q9UCW6; Q9UCW7; Q9UCW8;
DT   01-FEB-1995, integrated into UniProtKB/Swiss-Prot.
DT   30-APR-2003, sequence version 2.
DT   07-APR-2021, entry version 193.
DE   RecName: Full=Corticosteroid 11-beta-dehydrogenase isozyme 2 {ECO:0000305};
DE            EC=1.1.1.-;
DE   AltName: Full=11-beta-hydroxysteroid dehydrogenase type 2;
DE            Short=11-DH2;
DE            Short=11-beta-HSD2;
DE   AltName: Full=11-beta-hydroxysteroid dehydrogenase type II;
DE            Short=11-HSD type II;
DE            Short=11-beta-HSD type II;
DE   AltName: Full=NAD-dependent 11-beta-hydroxysteroid dehydrogenase;
DE            Short=11-beta-HSD;
DE   AltName: Full=Short chain dehydrogenase/reductase family 9C member 3;
GN   Name=HSD11B2 {ECO:0000312|HGNC:HGNC:5209};
GN   Synonyms=HSD11K {ECO:0000303|PubMed:8530071}, SDR9C3;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA], CATALYTIC ACTIVITY, AND FUNCTION.
RC   TISSUE=Kidney;
RX   PubMed=7859916; DOI=10.1016/0303-7207(94)90176-7;
RA   Albiston A.L., Obeyesekere V.R., Smith R.E., Krozowski Z.S.;
RT   "Cloning and tissue distribution of the human 11 beta-hydroxysteroid
RT   dehydrogenase type 2 enzyme.";
RL   Mol. Cell. Endocrinol. 105:R11-R17(1994).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA], AND TISSUE SPECIFICITY.
RC   TISSUE=Kidney;
RX   PubMed=8530071; DOI=10.1006/geno.1995.1231;
RA   Agarwal A.K., Rogerson F.M., Mune T., White P.C.;
RT   "Gene structure and chromosomal localization of the human HSD11K gene
RT   encoding the kidney (type 2) isozyme of 11 beta-hydroxysteroid
RT   dehydrogenase.";
RL   Genomics 29:195-199(1995).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RC   TISSUE=Placenta;
RX   PubMed=8611140; DOI=10.1042/bj3131007;
RA   Brown R.W., Chapman K.E., Kotelevtsev Y., Yau J.L., Lindsay R.S., Brett L.,
RA   Leckie C., Murad P., Lyons V., Mullins J.J., Edwards C.R.W., Seckl J.R.;
RT   "Cloning and production of antisera to human placental 11 beta-
RT   hydroxysteroid dehydrogenase type 2.";
RL   Biochem. J. 313:1007-1017(1996).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA].
RG   SeattleSNPs variation discovery resource;
RL   Submitted (JUN-2007) to the EMBL/GenBank/DDBJ databases.
RN   [5]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA].
RG   NHLBI resequencing and genotyping service (RS&G);
RL   Submitted (DEC-2008) to the EMBL/GenBank/DDBJ databases.
RN   [6]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA   Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L., Mobarry C.M.,
RA   Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R., Flanigan M.J.,
RA   Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V., Hannenhalli S.,
RA   Turner R., Yooseph S., Lu F., Nusskern D.R., Shue B.C., Zheng X.H.,
RA   Zhong F., Delcher A.L., Huson D.H., Kravitz S.A., Mouchard L., Reinert K.,
RA   Remington K.A., Clark A.G., Waterman M.S., Eichler E.E., Adams M.D.,
RA   Hunkapiller M.W., Myers E.W., Venter J.C.;
RL   Submitted (JUL-2005) to the EMBL/GenBank/DDBJ databases.
RN   [7]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RC   TISSUE=Ovary;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA project:
RT   the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [8]
RP   PROTEIN SEQUENCE OF 19-24; 77-84; 102-112; 134-154; 191-198; 214-227;
RP   229-235; 256-266; 272-278 AND 375-401.
RC   TISSUE=Placenta;
RX   PubMed=8611186; DOI=10.1042/bj3130997;
RA   Brown R.W., Chapman K.E., Murad P., Edwards C.R., Seckl J.R.;
RT   "Purification of 11 beta-hydroxysteroid dehydrogenase type 2 from human
RT   placenta utilizing a novel affinity labelling technique.";
RL   Biochem. J. 313:997-1005(1996).
RN   [9]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 90-221.
RA   Amin H.K., Hoeppner W.;
RT   "Human hydroxysteroid dehydrogenase type 2 HSD11B2.";
RL   Submitted (JUL-2001) to the EMBL/GenBank/DDBJ databases.
RN   [10]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 182-211; 235-264 AND 325-354, AND
RP   VARIANTS AME CYS-186; CYS-208; 250-PRO-SER-251 AND 337-ARG-TYR-338 DELINS
RP   HIS.
RX   PubMed=7593417; DOI=10.1210/jcem.80.11.7593417;
RA   Wilson R.C., Harbison M.D., Krozowski Z.S., Funder J.W., Shackleton C.H.L.,
RA   Hanauske-Abel H.M., Wei J.-Q., Hertecant J., Moran A., Neiberger R.E.,
RA   Balfe J.W., Fattah A., Daneman D., Licholai T., New M.I.;
RT   "Several homozygous mutations in the gene for 11 beta-hydroxysteroid
RT   dehydrogenase type 2 in patients with apparent mineralocorticoid excess.";
RL   J. Clin. Endocrinol. Metab. 80:3145-3150(1995).
RN   [11]
RP   CHARACTERIZATION.
RX   PubMed=2889032; DOI=10.1016/s0140-6736(87)91014-2;
RA   Stewart P.M., Wallace A.M., Valentino R., Burt D., Shackleton C.H.L.,
RA   Edwards C.R.W.;
RT   "Mineralocorticoid activity of liquorice: 11-beta-hydroxysteroid
RT   dehydrogenase deficiency comes of age.";
RL   Lancet 2:821-824(1987).
RN   [12]
RP   INTERACTION WITH NR3C2.
RX   PubMed=11350956; DOI=10.1074/jbc.m100374200;
RA   Odermatt A., Arnold P., Frey F.J.;
RT   "The intracellular localization of the mineralocorticoid receptor is
RT   regulated by 11beta-hydroxysteroid dehydrogenase type 2.";
RL   J. Biol. Chem. 276:28484-28492(2001).
RN   [13]
RP   VARIANT AME CYS-337.
RX   PubMed=7608290; DOI=10.1210/jcem.80.7.7608290;
RA   Wilson R.C., Krozowski Z.S., Li K., Obeyesekere V.R., Razzaghy-Azar M.,
RA   Harbison M.D., Wei J.-Q., Shackleton C.H.L., Funder J.W., New M.I.;
RT   "A mutation in the HSD11B2 gene in a family with apparent mineralocorticoid
RT   excess.";
RL   J. Clin. Endocrinol. Metab. 80:2263-2266(1995).
RN   [14]
RP   CHARACTERIZATION OF VARIANTS AME CYS-208; CYS-213; 250-PRO-SER-251 AND
RP   337-ARG-TYR-338 DELINS HIS.
RX   PubMed=7670488; DOI=10.1038/ng0895-394;
RA   Mune T., Rogerson F.M., Nikkilae H., Agarwal A.K., White P.C.;
RT   "Human hypertension caused by mutations in the kidney isozyme of 11 beta-
RT   hydroxysteroid dehydrogenase.";
RL   Nat. Genet. 10:394-399(1995).
RN   [15]
RP   CHARACTERIZATION OF VARIANTS AME HIS-208 AND 337-ARG-TYR-338 DELINS HIS.
RX   PubMed=9398712; DOI=10.1210/jcem.82.12.4455;
RA   Kitanaka S., Katsumata N., Tanae A., Hibi I., Takeyama K., Fuse H.,
RA   Kato S., Tanaka T.;
RT   "A new compound heterozygous mutation in the 11 beta-hydroxysteroid
RT   dehydrogenase type 2 gene in a case of apparent mineralocorticoid excess.";
RL   J. Clin. Endocrinol. Metab. 82:4054-4058(1997).
RN   [16]
RP   CHARACTERIZATION OF VARIANT AME CYS-279.
RX   PubMed=9683587; DOI=10.1086/301955;
RA   Li A., Tedde R., Krozowski Z.S., Pala A., Li K.X.Z., Shackleton C.H.L.,
RA   Mantero F., Palermo M., Stewart P.M.;
RT   "Molecular basis for hypertension in the 'type II variant' of apparent
RT   mineralocorticoid excess.";
RL   Am. J. Hum. Genet. 63:370-379(1998).
RN   [17]
RP   VARIANTS AME CYS-186; CYS-208; ASN-244; ARG-250; 250-PRO-SER-251; CYS-337
RP   AND 337-ARG-TYR-338 DELINS HIS.
RX   PubMed=9661590; DOI=10.1210/jcem.83.7.4986;
RA   Dave-Sharma S., Wilson R.C., Harbison M.D., Newfield R., Azar M.R.,
RA   Krozowski Z.S., Funder J.W., Shackleton C.H.L., Bradlow H.L., Wei J.-Q.,
RA   Hertecant J., Moran A., Neiberger R.E., Balfe J.W., Fattah A., Daneman D.,
RA   Akkurt H.I., De Santis C., New M.I.;
RT   "Examination of genotype and phenotype relationships in 14 patients with
RT   apparent mineralocorticoid excess.";
RL   J. Clin. Endocrinol. Metab. 83:2244-2254(1998).
RN   [18]
RP   CHARACTERIZATION OF VARIANT AME CYS-213.
RX   PubMed=9851783; DOI=10.1210/jcem.83.12.5329;
RA   Rogoff D., Smolenicka Z., Bergada I., Vallejo G., Barontini M.,
RA   Heinrich J.J., Ferrari P.;
RT   "The codon 213 of the 11beta-hydroxysteroid dehydrogenase type 2 gene is a
RT   hot spot for mutations in apparent mineralocorticoid excess.";
RL   J. Clin. Endocrinol. Metab. 83:4391-4393(1998).
RN   [19]
RP   CHARACTERIZATION OF VARIANT HYPERTENSION LEU-227.
RX   PubMed=9707624; DOI=10.1073/pnas.95.17.10200;
RA   Wilson R.C., Dave-Sharma S., Wei J.-Q., Obeyesekere V.R., Li K.,
RA   Ferrari P., Krozowski Z.S., Shackleton C.H.L., Bradlow L., Wiens T.,
RA   New M.I.;
RT   "A genetic defect resulting in mild low-renin hypertension.";
RL   Proc. Natl. Acad. Sci. U.S.A. 95:10200-10205(1998).
RN   [20]
RP   CHARACTERIZATION OF VARIANTS AME CYS-213 AND VAL-328.
RX   PubMed=10489390; DOI=10.1161/01.hyp.34.3.435;
RA   Morineau G., Marc J.-M., Boudi A., Galons H., Gourmelen M., Corvol P.,
RA   Pascoe L., Fiet J.;
RT   "Genetic, biochemical, and clinical studies of patients with A328V or R213C
RT   mutations in 11betaHSD2 causing apparent mineralocorticoid excess.";
RL   Hypertension 34:435-441(1999).
RN   [21]
RP   CHARACTERIZATION OF VARIANTS AME ARG-179; PHE-180; HIS-208; VAL-237 AND
RP   VAL-328.
RX   PubMed=10523339; DOI=10.1161/01.hyp.34.4.638;
RA   Nunez B.S., Rogerson F.M., Mune T., Igarashi Y., Nakagawa Y., Phillipov G.,
RA   Moudgil A., Travis L.B., Palermo M., Shackleton C.H.L., White P.C.;
RT   "Mutants of 11beta-hydroxysteroid dehydrogenase (11-HSD2) with partial
RT   activity: improved correlations between genotype and biochemical phenotype
RT   in apparent mineralocorticoid excess.";
RL   Hypertension 34:638-642(1999).
RN   [22]
RP   CHARACTERIZATION OF VARIANT AME 114-LEU-GLU-115 DEL, AND MUTAGENESIS OF
RP   GLU-115.
RX   PubMed=11238516; DOI=10.1210/jcem.86.3.7334;
RA   Odermatt A., Dick B., Arnold P., Zaehner T., Plueschke V., Deregibus M.N.,
RA   Repetto H., Frey B.M., Frey F.J., Ferrari P.;
RT   "A mutation in the cofactor-binding domain of 11beta-hydroxysteroid
RT   dehydrogenase type 2 associated with mineralocorticoid hypertension.";
RL   J. Clin. Endocrinol. Metab. 86:1247-1252(2001).
RN   [23]
RP   VARIANT AME ASN-223, AND BIOPHYSICOCHEMICAL PROPERTIES.
RX   PubMed=12788846; DOI=10.1210/jc.2002-021909;
RA   Carvajal C.A., Gonzalez A.A., Romero D.G., Gonzalez A., Mosso L.M.,
RA   Lagos E.T., Hevia Mdel P., Rosati M.P., Perez-Acle T.O.,
RA   Gomez-Sanchez C.E., Montero J.A., Fardella C.E.;
RT   "Two homozygous mutations in the 11 beta-hydroxysteroid dehydrogenase type
RT   2 gene in a case of apparent mineralocorticoid excess.";
RL   J. Clin. Endocrinol. Metab. 88:2501-2507(2003).
RN   [24]
RP   VARIANTS AME CYS-337 AND HIS-338, SUBCELLULAR LOCATION, BIOPHYSICOCHEMICAL
RP   PROPERTIES, AND MUTAGENESIS OF ARG-335; ARG-336; ARG-337; TYR-338 AND
RP   TYR-339.
RX   PubMed=17314322; DOI=10.1681/asn.2006111235;
RA   Atanasov A.G., Ignatova I.D., Nashev L.G., Dick B., Ferrari P., Frey F.J.,
RA   Odermatt A.;
RT   "Impaired protein stability of 11beta-hydroxysteroid dehydrogenase type 2:
RT   a novel mechanism of apparent mineralocorticoid excess.";
RL   J. Am. Soc. Nephrol. 18:1262-1270(2007).
CC   -!- FUNCTION: Catalyzes the conversion of cortisol to the inactive
CC       metabolite cortisone. Modulates intracellular glucocorticoid levels,
CC       thus protecting the nonselective mineralocorticoid receptor from
CC       occupation by glucocorticoids. {ECO:0000269|PubMed:7859916}.
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=an 11beta-hydroxysteroid + NAD(+) = an 11-oxosteroid + H(+) +
CC         NADH; Xref=Rhea:RHEA:53116, ChEBI:CHEBI:15378, ChEBI:CHEBI:35346,
CC         ChEBI:CHEBI:47787, ChEBI:CHEBI:57540, ChEBI:CHEBI:57945;
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=corticosterone + NAD(+) = 11-dehydrocorticosterone + H(+) +
CC         NADH; Xref=Rhea:RHEA:42204, ChEBI:CHEBI:15378, ChEBI:CHEBI:16827,
CC         ChEBI:CHEBI:57540, ChEBI:CHEBI:57945, ChEBI:CHEBI:78600;
CC         Evidence={ECO:0000269|PubMed:7859916};
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=cortisol + NAD(+) = cortisone + H(+) + NADH;
CC         Xref=Rhea:RHEA:50208, ChEBI:CHEBI:15378, ChEBI:CHEBI:16962,
CC         ChEBI:CHEBI:17650, ChEBI:CHEBI:57540, ChEBI:CHEBI:57945;
CC         Evidence={ECO:0000269|PubMed:7859916};
CC   -!- ACTIVITY REGULATION: Inhibited by glycyrrhetinic acid (derived from
CC       liquorice), carbenoloxone and 11-alpha-OH-progesterone. {ECO:0000250}.
CC   -!- BIOPHYSICOCHEMICAL PROPERTIES:
CC       Kinetic parameters:
CC         KM=26.1 nM for cortisol {ECO:0000269|PubMed:12788846,
CC         ECO:0000269|PubMed:17314322};
CC         KM=785 nM for cortisol {ECO:0000269|PubMed:12788846,
CC         ECO:0000269|PubMed:17314322};
CC         KM=77 nM for cortisterone {ECO:0000269|PubMed:12788846,
CC         ECO:0000269|PubMed:17314322};
CC         Vmax=64.1 nmol/h/mg enzyme toward cortisterone
CC         {ECO:0000269|PubMed:12788846, ECO:0000269|PubMed:17314322};
CC         Vmax=66 nmol/h/mg enzyme toward cortisol
CC         {ECO:0000269|PubMed:12788846, ECO:0000269|PubMed:17314322};
CC   -!- SUBUNIT: Interacts with ligand-free cytoplasmic NR3C2.
CC       {ECO:0000269|PubMed:11350956}.
CC   -!- SUBCELLULAR LOCATION: Microsome {ECO:0000269|PubMed:17314322}.
CC       Endoplasmic reticulum {ECO:0000269|PubMed:17314322}.
CC   -!- TISSUE SPECIFICITY: Expressed in kidney, pancreas, prostate, ovary,
CC       small intestine and colon. At midgestation, expressed at high levels in
CC       placenta and in fetal kidney and, at much lower levels, in fetal lung
CC       and testis (PubMed:8530071). {ECO:0000269|PubMed:8530071}.
CC   -!- DISEASE: Apparent mineralocorticoid excess (AME) [MIM:218030]: An
CC       autosomal recessive form of low-renin hypertension. It is usually
CC       diagnosed within the first years of life and is characterized by
CC       polyuria and polydipsia, failure to thrive, hypernatremia, severe
CC       hypertension with low renin and aldosterone levels, profound
CC       hypokalemia with metabolic alkalosis, and most often nephrocalcinosis.
CC       {ECO:0000269|PubMed:10489390, ECO:0000269|PubMed:10523339,
CC       ECO:0000269|PubMed:11238516, ECO:0000269|PubMed:12788846,
CC       ECO:0000269|PubMed:17314322, ECO:0000269|PubMed:7593417,
CC       ECO:0000269|PubMed:7608290, ECO:0000269|PubMed:7670488,
CC       ECO:0000269|PubMed:9398712, ECO:0000269|PubMed:9661590,
CC       ECO:0000269|PubMed:9683587, ECO:0000269|PubMed:9851783}. Note=The
CC       disease is caused by variants affecting the gene represented in this
CC       entry.
CC   -!- MISCELLANEOUS: Consumption of large amounts of liquorice can lead to
CC       apparent mineralocorticoid excess and hypertension.
CC   -!- SIMILARITY: Belongs to the short-chain dehydrogenases/reductases (SDR)
CC       family. {ECO:0000305}.
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; U14631; AAA91969.1; -; mRNA.
DR   EMBL; U27317; AAB48544.1; -; Genomic_DNA.
DR   EMBL; U26726; AAC50356.1; -; mRNA.
DR   EMBL; EF694683; ABS29267.1; -; Genomic_DNA.
DR   EMBL; FJ515828; ACS13714.1; -; Genomic_DNA.
DR   EMBL; CH471092; EAW83134.1; -; Genomic_DNA.
DR   EMBL; BC036780; AAH36780.1; -; mRNA.
DR   EMBL; BC064536; AAH64536.1; -; mRNA.
DR   EMBL; AY046280; AAK91586.1; -; Genomic_DNA.
DR   CCDS; CCDS10837.1; -.
DR   PIR; S62789; S62789.
DR   RefSeq; NP_000187.3; NM_000196.3.
DR   BioGRID; 109524; 7.
DR   STRING; 9606.ENSP00000316786; -.
DR   BindingDB; P80365; -.
DR   ChEMBL; CHEMBL3746; -.
DR   DrugBank; DB01234; Dexamethasone.
DR   DrugBank; DB14649; Dexamethasone acetate.
DR   DrugBank; DB00687; Fludrocortisone.
DR   DrugBank; DB01185; Fluoxymesterone.
DR   DrugBank; DB01569; Formebolone.
DR   DrugBank; DB00741; Hydrocortisone.
DR   DrugBank; DB14538; Hydrocortisone aceponate.
DR   DrugBank; DB14539; Hydrocortisone acetate.
DR   DrugBank; DB14540; Hydrocortisone butyrate.
DR   DrugBank; DB14541; Hydrocortisone cypionate.
DR   DrugBank; DB14542; Hydrocortisone phosphate.
DR   DrugBank; DB14543; Hydrocortisone probutate.
DR   DrugBank; DB14544; Hydrocortisone valerate.
DR   DrugBank; DB00959; Methylprednisolone.
DR   DrugBank; DB00157; NADH.
DR   DrugBank; DB14631; Prednisolone phosphate.
DR   DrugCentral; P80365; -.
DR   GuidetoPHARMACOLOGY; 3143; -.
DR   SwissLipids; SLP:000000810; -.
DR   iPTMnet; P80365; -.
DR   PhosphoSitePlus; P80365; -.
DR   BioMuta; HSD11B2; -.
DR   DMDM; 30316367; -.
DR   EPD; P80365; -.
DR   jPOST; P80365; -.
DR   MassIVE; P80365; -.
DR   MaxQB; P80365; -.
DR   PaxDb; P80365; -.
DR   PeptideAtlas; P80365; -.
DR   PRIDE; P80365; -.
DR   ProteomicsDB; 57680; -.
DR   Antibodypedia; 29548; 311 antibodies.
DR   Ensembl; ENST00000326152; ENSP00000316786; ENSG00000176387.
DR   GeneID; 3291; -.
DR   KEGG; hsa:3291; -.
DR   UCSC; uc002etd.4; human.
DR   CTD; 3291; -.
DR   DisGeNET; 3291; -.
DR   GeneCards; HSD11B2; -.
DR   HGNC; HGNC:5209; HSD11B2.
DR   HPA; ENSG00000176387; Tissue enhanced (intestine, kidney, salivary gland).
DR   MalaCards; HSD11B2; -.
DR   MIM; 218030; phenotype.
DR   MIM; 614232; gene.
DR   neXtProt; NX_P80365; -.
DR   OpenTargets; ENSG00000176387; -.
DR   Orphanet; 320; Apparent mineralocorticoid excess.
DR   PharmGKB; PA29477; -.
DR   VEuPathDB; HostDB:ENSG00000176387.6; -.
DR   eggNOG; KOG1610; Eukaryota.
DR   GeneTree; ENSGT00940000159716; -.
DR   HOGENOM; CLU_010194_2_0_1; -.
DR   InParanoid; P80365; -.
DR   OMA; ATFRNCM; -.
DR   OrthoDB; 1313182at2759; -.
DR   PhylomeDB; P80365; -.
DR   TreeFam; TF325617; -.
DR   BRENDA; 1.1.1.B40; 2681.
DR   PathwayCommons; P80365; -.
DR   Reactome; R-HSA-194002; Glucocorticoid biosynthesis.
DR   SABIO-RK; P80365; -.
DR   SIGNOR; P80365; -.
DR   BioGRID-ORCS; 3291; 11 hits in 985 CRISPR screens.
DR   ChiTaRS; HSD11B2; human.
DR   GeneWiki; Corticosteroid_11-beta-dehydrogenase_isozyme_2; -.
DR   GenomeRNAi; 3291; -.
DR   Pharos; P80365; Tchem.
DR   PRO; PR:P80365; -.
DR   Proteomes; UP000005640; Chromosome 16.
DR   RNAct; P80365; protein.
DR   Bgee; ENSG00000176387; Expressed in adult mammalian kidney and 133 other tissues.
DR   ExpressionAtlas; P80365; baseline and differential.
DR   Genevisible; P80365; HS.
DR   GO; GO:0005789; C:endoplasmic reticulum membrane; TAS:Reactome.
DR   GO; GO:0005811; C:lipid droplet; IDA:HPA.
DR   GO; GO:0005654; C:nucleoplasm; IDA:HPA.
DR   GO; GO:0003845; F:11-beta-hydroxysteroid dehydrogenase [NAD(P)] activity; IEA:Ensembl.
DR   GO; GO:0051287; F:NAD binding; IEA:Ensembl.
DR   GO; GO:0005496; F:steroid binding; IEA:Ensembl.
DR   GO; GO:0007565; P:female pregnancy; IEA:Ensembl.
DR   GO; GO:0006704; P:glucocorticoid biosynthetic process; TAS:Reactome.
DR   GO; GO:0002017; P:regulation of blood volume by renal aldosterone; IEA:Ensembl.
DR   GO; GO:0042493; P:response to drug; IEA:Ensembl.
DR   GO; GO:0032094; P:response to food; IEA:Ensembl.
DR   GO; GO:0051384; P:response to glucocorticoid; IEA:Ensembl.
DR   GO; GO:0001666; P:response to hypoxia; IEA:Ensembl.
DR   GO; GO:0032868; P:response to insulin; IEA:Ensembl.
DR   InterPro; IPR036291; NAD(P)-bd_dom_sf.
DR   InterPro; IPR020904; Sc_DH/Rdtase_CS.
DR   InterPro; IPR002347; SDR_fam.
DR   Pfam; PF00106; adh_short; 1.
DR   PRINTS; PR00081; GDHRDH.
DR   SUPFAM; SSF51735; SSF51735; 1.
DR   PROSITE; PS00061; ADH_SHORT; 1.
PE   1: Evidence at protein level;
KW   Direct protein sequencing; Disease variant; Endoplasmic reticulum;
KW   Microsome; NAD; Oxidoreductase; Reference proteome.
FT   CHAIN           1..405
FT                   /note="Corticosteroid 11-beta-dehydrogenase isozyme 2"
FT                   /id="PRO_0000054627"
FT   NP_BIND         82..111
FT                   /note="NAD"
FT                   /evidence="ECO:0000250"
FT   REGION          335..339
FT                   /note="Essential for protein stability"
FT   ACT_SITE        232
FT                   /note="Proton acceptor"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU10001"
FT   BINDING         219
FT                   /note="Substrate"
FT                   /evidence="ECO:0000250"
FT   VARIANT         114..115
FT                   /note="Missing (in AME; reduces enzyme activity by at least
FT                   95%)"
FT                   /evidence="ECO:0000269|PubMed:11238516"
FT                   /id="VAR_015634"
FT   VARIANT         147
FT                   /note="R -> H (in dbSNP:rs13306425)"
FT                   /id="VAR_052317"
FT   VARIANT         179
FT                   /note="L -> R (in AME; abolishes enzyme activity)"
FT                   /evidence="ECO:0000269|PubMed:10523339"
FT                   /id="VAR_015635"
FT   VARIANT         180
FT                   /note="S -> F (in AME; reduces enzyme activity)"
FT                   /evidence="ECO:0000269|PubMed:10523339"
FT                   /id="VAR_015636"
FT   VARIANT         186
FT                   /note="R -> C (in AME; dbSNP:rs768507002)"
FT                   /evidence="ECO:0000269|PubMed:7593417,
FT                   ECO:0000269|PubMed:9661590"
FT                   /id="VAR_015637"
FT   VARIANT         208
FT                   /note="R -> C (in AME; reduces enzyme activity by at least
FT                   95%; dbSNP:rs121917780)"
FT                   /evidence="ECO:0000269|PubMed:7593417,
FT                   ECO:0000269|PubMed:7670488, ECO:0000269|PubMed:9661590"
FT                   /id="VAR_006958"
FT   VARIANT         208
FT                   /note="R -> H (in AME; abolishes enzyme activity;
FT                   dbSNP:rs28934592)"
FT                   /evidence="ECO:0000269|PubMed:10523339,
FT                   ECO:0000269|PubMed:9398712"
FT                   /id="VAR_015638"
FT   VARIANT         213
FT                   /note="R -> C (in AME; reduces enzyme activity by 90%;
FT                   dbSNP:rs28934591)"
FT                   /evidence="ECO:0000269|PubMed:10489390,
FT                   ECO:0000269|PubMed:7670488, ECO:0000269|PubMed:9851783"
FT                   /id="VAR_006959"
FT   VARIANT         223
FT                   /note="D -> N (in AME; reduces enzyme activity to about 6%
FT                   of wild type; dbSNP:rs121917833)"
FT                   /evidence="ECO:0000269|PubMed:12788846"
FT                   /id="VAR_066514"
FT   VARIANT         227
FT                   /note="P -> L (in hypertension; decreases affinity for
FT                   cortisol; dbSNP:rs121917782)"
FT                   /evidence="ECO:0000269|PubMed:9707624"
FT                   /id="VAR_015639"
FT   VARIANT         237
FT                   /note="A -> V (in AME; reduces enzyme activity;
FT                   dbSNP:rs1309642469)"
FT                   /evidence="ECO:0000269|PubMed:10523339"
FT                   /id="VAR_015640"
FT   VARIANT         244
FT                   /note="D -> N (in AME; associated with R-250)"
FT                   /evidence="ECO:0000269|PubMed:9661590"
FT                   /id="VAR_015641"
FT   VARIANT         250..251
FT                   /note="LL -> PS (in AME; abolishes enzyme activity)"
FT                   /id="VAR_015643"
FT   VARIANT         250
FT                   /note="L -> R (in AME; associated with N-244)"
FT                   /evidence="ECO:0000269|PubMed:9661590"
FT                   /id="VAR_015642"
FT   VARIANT         279
FT                   /note="R -> C (in AME; decreases enzyme activity by 33%;
FT                   dbSNP:rs28934594)"
FT                   /evidence="ECO:0000269|PubMed:9683587"
FT                   /id="VAR_015644"
FT   VARIANT         328
FT                   /note="A -> V (in AME; abolishes enzyme activity;
FT                   dbSNP:rs1453036708)"
FT                   /evidence="ECO:0000269|PubMed:10489390,
FT                   ECO:0000269|PubMed:10523339"
FT                   /id="VAR_015645"
FT   VARIANT         337..338
FT                   /note="RY -> H (in AME; abolishes enzyme activity)"
FT                   /evidence="ECO:0000269|PubMed:7593417,
FT                   ECO:0000269|PubMed:7670488, ECO:0000269|PubMed:9398712,
FT                   ECO:0000269|PubMed:9661590"
FT                   /id="VAR_015647"
FT   VARIANT         337
FT                   /note="R -> C (in AME; decreased half-life from 21 to 4
FT                   hours compared to wild-type, probably due to degradation
FT                   via the proteasomal pathway; dbSNP:rs121917781)"
FT                   /evidence="ECO:0000269|PubMed:17314322,
FT                   ECO:0000269|PubMed:7608290, ECO:0000269|PubMed:9661590"
FT                   /id="VAR_066515"
FT   VARIANT         338
FT                   /note="Y -> H (in AME; abolishes enzyme activity; decreased
FT                   half-life from 21 to 3 hours compared to wild-type,
FT                   probably due to degradation via the proteasomal pathway;
FT                   dbSNP:rs387907117)"
FT                   /evidence="ECO:0000269|PubMed:17314322"
FT                   /id="VAR_015646"
FT   MUTAGEN         115
FT                   /note="E->K,Q: Abolishes cofactor specificity."
FT                   /evidence="ECO:0000269|PubMed:11238516"
FT   MUTAGEN         335
FT                   /note="R->A,Q: Reduced enzyme activity."
FT                   /evidence="ECO:0000269|PubMed:17314322"
FT   MUTAGEN         335
FT                   /note="R->K: No effect on enzyme activity."
FT                   /evidence="ECO:0000269|PubMed:17314322"
FT   MUTAGEN         336
FT                   /note="R->A,Q: Almost complete loss of enzyme activity."
FT                   /evidence="ECO:0000269|PubMed:17314322"
FT   MUTAGEN         336
FT                   /note="R->K: Reduced enzyme activity."
FT                   /evidence="ECO:0000269|PubMed:17314322"
FT   MUTAGEN         337
FT                   /note="R->A,Q: Almost complete loss of enzyme activity."
FT                   /evidence="ECO:0000269|PubMed:17314322"
FT   MUTAGEN         337
FT                   /note="R->K: Reduced enzyme activity."
FT                   /evidence="ECO:0000269|PubMed:17314322"
FT   MUTAGEN         338
FT                   /note="Y->F,A: Complete loss of enzyme activity."
FT                   /evidence="ECO:0000269|PubMed:17314322"
FT   MUTAGEN         339
FT                   /note="Y->A,F,H: Reduced enzyme activity."
FT                   /evidence="ECO:0000269|PubMed:17314322"
FT   CONFLICT        148
FT                   /note="V -> F (in Ref. 2; AAB48544)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        148
FT                   /note="V -> L (in Ref. 1; AAA91969)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        350
FT                   /note="I -> T (in Ref. 7; AAH64536)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        392
FT                   /note="D -> G (in Ref. 7; AAH36780)"
FT                   /evidence="ECO:0000305"
SQ   SEQUENCE   405 AA;  44127 MW;  4AB269E269982D24 CRC64;
     MERWPWPSGG AWLLVAARAL LQLLRSDLRL GRPLLAALAL LAALDWLCQR LLPPPAALAV
     LAAAGWIALS RLARPQRLPV ATRAVLITGC DSGFGKETAK KLDSMGFTVL ATVLELNSPG
     AIELRTCCSP RLRLLQMDLT KPGDISRVLE FTKAHTTSTG LWGLVNNAGH NEVVADAELS
     PVATFRSCME VNFFGALELT KGLLPLLRSS RGRIVTVGSP AGDMPYPCLG AYGTSKAAVA
     LLMDTFSCEL LPWGVKVSII QPGCFKTESV RNVGQWEKRK QLLLANLPQE LLQAYGKDYI
     EHLHGQFLHS LRLAMSDLTP VVDAITDALL AARPRRRYYP GQGLGLMYFI HYYLPEGLRR
     RFLQAFFISH CLPRALQPGQ PGTTPPQDAA QDPNLSPGPS PAVAR
//
